ClinicalTrials.gg
CompletedNCT00539630Updated Oct 4, 2007

TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN

A Phase 3 interventional study of Docetaxel in Carcinoma, Squamous Cell, sponsored by Sanofi. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2007-10-04.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 20 studies testing docetaxel in Carcinoma, Squamous Cell — 3 open to participants now, 3 under way, none of them phase 3. Docetaxel · Carcinoma, Squamous Cell.

Enrollment
6th of 20
86 · median 33
Started
2002
the only one that year
Phase 3
2 of 20
none open now
Registered
5th of 20
by date
Lead sponsor
2 of 20
Sanofi

Among the 20 studies testing docetaxel in Carcinoma, Squamous Cell, this one is the 6th largest by enrollment, is the only one that started in 2002, is one of 2 in phase 3, and was the 5th registered.

Carcinoma, Squamous Cell

629 studies on the registry are indexed under Carcinoma, Squamous Cell; 135 are open to participants now.

Browse Carcinoma, Squamous Cell studies →

Open to participants now

3 of the 20 studies testing docetaxel in Carcinoma, Squamous Cell are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Carcinoma, Squamous Cell studies recruiting now, 86 (84%) set no upper age limit and 8 (8%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing docetaxel in Carcinoma, Squamous Cell, or all of them as a file.
02

Study summary

To describe the clinical response rate in two groups (Docetaxel plus cisplatin plus 5-FU, versus Cisplatin plus 5-FU) after 3 cycle of neoadjuvant chemotherapy.

03

Conditions studied

  • Carcinoma, Squamous Cell
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically proven squamous cell carcinoma of the head and neck with locally advanced inoperable disease.
  • Primary tumor sites eligible: oral cavity, oropharynx, hypopharynx , larynx or nasopharynx.
  • Patients are required to have at least one (bi-or uni-dimensionally) .
  • 0 or 1.
  • Adequate bone marrow, hepatic and renal functions.

Exclusion criteria

Exclusion Criteria:

  • Pregnant and lactating women
  • Previous chemotherapy
  • Previous radiotherapy for H\&N
  • Previous surgery for H\&N

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
86 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical response will be evaluated by modified WHO criteria. Clinical and radiological assessment of all lesions will be performed

    Time frame: After 2 cycle, 3 cycle and after concurrent chemo/radiotherapy.

Secondary outcomes

  1. Pathologic response if clinical response of primary tumor is CR at the end of chemotherapy and end of concurrent chemo/ radiotherapy, biopsy of primary tumor site will be performed to evaluate pathologic response rate.

07

Study locations

1 site
  • Sanofi-Aventis
    Seoul, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 4, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00539630
Lead sponsor
Sanofi
First posted
Oct 4, 2007
Start date
Nov 2002
Last update
Oct 4, 2007

Study contacts

Hyang Rim Kim
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion